Profund Advisors LLC Raises Stake in Agios Pharmaceuticals, Inc. $AGIO

Profund Advisors LLC raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 163.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,850 shares of the biopharmaceutical company’s stock after acquiring an additional 24,741 shares during the quarter. Profund Advisors LLC owned approximately 0.07% of Agios Pharmaceuticals worth $1,085,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Assetmark Inc. lifted its stake in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 362 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals during the first quarter worth approximately $40,000. Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals during the third quarter worth approximately $79,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 588 shares in the last quarter. Finally, KBC Group NV raised its holdings in Agios Pharmaceuticals by 72.5% during the fourth quarter. KBC Group NV now owns 3,020 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 1,269 shares in the last quarter.

Key Stories Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Zacks Research raised its FY2026 earnings estimate for Agios Pharmaceuticals, implying a slightly better near-term outlook for the company. AGIO Free Report
• Positive Sentiment: The firm also lifted its FY2027 EPS estimate, another signal that analysts see some improvement in Agios’ longer-term profitability trajectory. AGIO Free Report
• Positive Sentiment: Several quarterly estimates were nudged higher, including Q2 2026, Q3 2026, Q2 2027 and Q3 2027, which may be supporting sentiment around the company’s earnings outlook. AGIO Free Report
• Neutral Sentiment: Other updates were mixed, with Zacks trimming its Q1 2027 and Q1 2028 EPS estimates and lowering FY2028 expectations, offsetting some of the more upbeat revisions. AGIO Free Report
• Negative Sentiment: The company still faces meaningful losses in the forecast period, with analysts expecting negative EPS through at least 2028, which underscores ongoing profitability risk. AGIO Free Report

Wall Street Analyst Weigh In

AGIO has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. JPMorgan Chase & Co. raised their price objective on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the stock a “neutral” rating in a report on Monday, April 6th. The Goldman Sachs Group raised their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Citigroup raised their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, HC Wainwright cut their price objective on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $41.56.

Insiders Place Their Bets

In other news, CFO Cecilia Jones sold 3,141 shares of Agios Pharmaceuticals stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $109,024.11. Following the transaction, the chief financial officer directly owned 54,998 shares of the company’s stock, valued at $1,908,980.58. The trade was a 5.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James William Burns sold 3,280 shares of Agios Pharmaceuticals stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $113,848.80. Following the completion of the transaction, the insider directly owned 49,306 shares in the company, valued at $1,711,411.26. The trade was a 6.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 15,582 shares of company stock worth $520,405. Corporate insiders own 5.40% of the company’s stock.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock opened at $28.79 on Friday. The firm’s fifty day simple moving average is $29.61 and its 200-day simple moving average is $29.57. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -3.97 and a beta of 0.58. Agios Pharmaceuticals, Inc. has a 12 month low of $22.24 and a 12 month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. The business had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $13.30 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The firm’s revenue was up 137.7% compared to the same quarter last year. Analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.17 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.